The approval of the first KRAS-targeting drug by the FDA in 2021 marked a significant milestone, opening new avenues for precision medicine. However, the clinical success of KRAS inhibitors has been tempered by the adaptive capabilities of cancer cells. These cells, adept at circumventing single-agent therapies, frequently upregulate compensatory signaling pathways, thereby sustaining their growth and survival. Addressing this, researchers at the University of Cincinnati Cancer Center, led by Joan Garrett, PhD, are pioneering a novel combination approach aimed at simultaneously targeting KRAS mutations and the HER family of receptors, particularly HER3, which play a pivotal role in tumor cell resilience.

Dr. Garrett’s research builds on findings from her laboratory that reveal an intriguing biological feedback loop: colorectal cancer cells treated with KRAS inhibitors exhibit increased HER3 expression. This upregulation serves as an escape mechanism, enabling tumor cells to persist despite KRAS blockade. By co-inhibiting both KRAS and HER family members, the research aims to disrupt this adaptive signaling network, potentially enhancing therapeutic efficacy and overcoming drug resistance.

Funded by a two-year, $162,000 grant from the National Cancer Institute, Dr. Garrett’s study leverages patient-derived xenografts (PDXs)—animal models implanted with human tumor tissues—to closely mimic the complex tumor environment found in patients. Unlike conventional cell cultures grown on plastic, PDXs retain the heterogeneity and architecture of primary tumors, providing a more clinically relevant platform to assess drug responses. This methodology is crucial for evaluating the synergistic effects and safety of combined KRAS and HER3 inhibition in a setting that closely recapitulates human disease.

The experimental strategy involves treating these PDX models with a combination of KRAS inhibitors and various HER3-targeted agents. The research team is meticulously analyzing whether this dual-targeted approach yields superior tumor suppression compared to monotherapies. Early indications suggest that co-targeting these pathways may disrupt key survival signals within cancer cells, thereby potentiating apoptosis and inhibiting proliferation more effectively.

If successful, this innovative therapy paradigm could significantly alter the management of metastatic colorectal cancer, a condition notorious for its poor prognosis and limited treatment options once the cancer has spread beyond the colon. Targeted therapies that exploit specific genetic vulnerabilities promise to extend patient survival while minimizing toxic side effects typically associated with traditional chemotherapies.

Dr. Garrett emphasizes the clinical importance of developing treatments that are not only more effective but also less harmful. Targeted agents generally exhibit a more favorable toxicity profile, sparing normal cells and reducing adverse effects. This approach aligns with the broader trend in oncology toward precision medicine—delivering interventions tailored to the unique molecular characteristics of each patient’s tumor.

The timing of this research is particularly auspicious given recent advances in the field. Over the past five years, the development and FDA approval of KRAS inhibitors have revolutionized therapeutic strategies for cancers harboring these mutations. Numerous ongoing clinical trials are evaluating these agents across various cancer types, underscoring the momentum and promise of KRAS-targeted therapies.

While the initial success of KRAS inhibitors is encouraging, the emergence of resistance mechanisms such as HER3-mediated survival pathways underscores the complexity of cancer biology and the necessity of combination therapies. Dr. Garrett’s work represents a crucial step toward comprehensive molecular targeting that anticipates and counters tumor adaptability.

The promise of this research extends beyond colorectal cancer. Given the prevalence of KRAS mutations and HER family involvement across multiple malignancies, insights gained from this study may inform treatment paradigms in other cancers, potentially broadening the impact of this combination strategy.

As this project advances, collaboration between molecular biologists, pharmacologists, and clinical oncologists will be essential to translate preclinical findings into effective patient therapies. The integration of sophisticated models like patient-derived xenografts will continue to be instrumental in refining therapeutic regimens before clinical application.

In a field marked by incremental progress, the work led by Joan Garrett, PhD, exemplifies the innovative, multi-faceted approaches necessary to outsmart complex diseases like colorectal cancer. Through strategic combination therapies aimed at critical oncogenic pathways, there is renewed hope for improving outcomes and extending the lives of patients afflicted by this devastating disease.

Subject of Research: Combination therapy targeting KRAS mutations and HER family receptors in colorectal cancer

Article Title: University of Cincinnati Scientist Investigates Novel KRAS and HER3 Dual-Inhibition Strategy for Colorectal Cancer

News Publication Date: 2024

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/353a2132-6e5b-47e9-aba5-0669e59be4b6/Rendition/low-res/Content/Public

References:
Research supported by the National Cancer Institute of the National Institutes of Health under Award Number 1R03CA304041-0

Image Credits: Photo/Colleen Kelley/UC Marketing + Brand

Keywords: Colorectal cancer, KRAS mutation, HER3, targeted therapy, combination therapy, patient-derived xenografts, cancer resistance mechanisms, FDA-approved KRAS inhibitors, precision medicine

One of the most challenging dilemmas in oncology today involves the treatment of recurrent head and neck malignancies. Patients face daunting risks of disease recurrence and secondary cancers, with surgical options often limited due to tumor location or prior interventions. Addressing this precision gap, Dr. Taylor MacDonald and colleagues have meticulously reviewed 84 cases of proton re-irradiation at the Cancer Center. Their analysis reveals a sobering reality: more than 63% of patients experienced further disease progression within just four months post-treatment, while the one-year overall survival rate stood at 33%.

Proton re-irradiation represents a sophisticated modality whereby targeted proton beams deliver an additional course of radiation therapy to previously irradiated tissues, employing the physical properties of protons to minimize damage to surrounding healthy cells. MacDonald highlights that in absence of an established standard of care for recurrent cases, proton therapy provides an invaluable tool for enhancing local tumor control. Despite high-grade toxicities observed, these side effects were generally manageable, underscoring the critical need for judicious patient selection to balance therapeutic benefits against potential harms.

Looking ahead, the research team is focused on dissecting factors that exacerbate toxicity, particularly in patients with base-of-skull tumor recurrence—a subgroup for which long-term photon irradiation data remains scant. Their investigations are poised to inform safety enhancements and optimization of re-irradiation protocols that may transform outcomes in this recalcitrant patient population.

Complementing this work, Dr. Morgan Bailey and collaborators have conducted an insightful survey of expert radiation oncologists treating oropharyngeal cancers. Despite the prevalence of nearly 60,000 new oral cavity and oropharyngeal cancer cases annually in the United States, no standardized treatment paradigm has emerged. The survey exposed significant heterogeneity in therapeutic approaches among specialists across institutions, with implications reverberating from clinical trials to resident education and patient prognosis.

This stark variability reflects the complex interplay of tumor biology, technological capabilities, and clinician experience when navigating oropharyngeal cancer treatments. Bailey stresses how these findings urge a concerted effort to harmonize clinical guidelines and consolidate expertise in specialized academic centers to foster consistency that ultimately benefits patient outcomes.

Turning to hepatic malignancies, hepatocellular carcinoma (HCC) presents formidable therapeutic challenges due to its high intrahepatic recurrence rates and proximity to critical radiosensitive structures. Dr. Sarah Feldkamp’s study probes the safety profile of ablative radiation—a modality delivering concentrated high doses tailored to eradicate tumors—with an emphasis on hepatobiliary toxicity following treatment of centrally located HCC lesions. Remarkably, severe hepatobiliary complications were rare despite substantial radiation doses administered near sensitive biliary anatomy, indicating a favorable therapeutic index.

Such findings illuminate the increasing feasibility of precise ablative radiotherapy in managing difficult-to-treat liver tumors while preserving vital organ function. Feldkamp’s team intends to delve deeper into comparative toxicity across various ablative radiation regimens to further refine treatment planning and safeguard patient health.

Another pioneering evaluation from the same group examines the integration of patient-reported outcomes alongside clinician assessments in hypofractionated whole pelvis radiation for endometrial cancer. Hypofractionation shortens treatment duration by administering higher radiation doses per fraction, a strategy that has revolutionized breast and prostate cancer care. Their Phase 1 trial reveals a discrepancy: patients report higher rates of toxicity events compared to clinician evaluations, yet this does not correlate with diminished quality of life metrics.

This divergence underscores the intrinsic limitations of physician-only toxicity assessments and advocates for incorporating patient perspectives to capture the full spectrum of treatment impact. Feldkamp emphasizes that optimizing hypofractionated protocols could significantly improve convenience and adherence for endometrial cancer patients, pending validation of safety and efficacy.

Beyond these core studies, additional abstracts from the Cancer Center expand the frontier of radiation oncology knowledge. Jessica Ortega’s upcoming presentation investigates radiation necrosis, pseudoprogression, and radiologic changes after photon or proton chemoradiotherapy in IDH-mutated Grade 2-3 gliomas—tumors with distinct molecular and clinical profiles requiring nuanced therapeutic approaches.

Together, these comprehensive research efforts from the University of Cincinnati Cancer Center embody a relentless pursuit to enhance radiation oncology practice, guided by robust data and patient-centered inquiry. As technology advances and multidisciplinary collaboration deepens, these insights herald a new era of precision tailored not only to tumor biology but also to individual patient experience and safety.

Subject of Research: Radiation Oncology – Proton Re-irradiation in Head and Neck Cancers, Oropharyngeal Cancer Treatment Patterns, Hepatobiliary Toxicity in Liver Cancer, Hypofractionated Radiation in Endometrial Cancer

Article Title: University of Cincinnati Cancer Center Reveals Pioneering Radiation Oncology Findings at ASTRO 2025

News Publication Date: Not provided

Web References: Not provided

References: Not provided

Image Credits: Not provided

Keywords: Liver cancer, proton re-irradiation, head and neck cancer, oropharyngeal cancer, hepatocellular carcinoma, ablative radiation, hypofractionated radiation therapy, endometrial cancer, radiation toxicity, patient-reported outcomes

PDAC’s tumor microenvironment is a highly complex ecosystem composed not only of malignant cells but also encompassing immune cells, vasculature, and stromal tissues. This dynamic and often hostile milieu orchestrates immune evasion, limiting the efficacy of immune-mediated tumor suppression. Traditional therapeutic modalities, including chemotherapy and radiotherapy, often fail to penetrate or effectively disrupt this microenvironment, resulting in poor clinical outcomes. The University of Cincinnati team focused their research on deciphering the molecular mechanisms underpinning this immunosuppressive landscape, with the aim of identifying new molecular targets for therapy.

At the center of their discovery is the heat shock protein 70 (Hsp70), a molecular chaperone long recognized for its essential role in maintaining cellular homeostasis under stress conditions. While Hsp70’s ubiquitous function in protein folding and protection from cellular stress is well established, its specific involvement in facilitating immune suppression within the PDAC tumor microenvironment was previously underappreciated. The research unveiled that Hsp70 plays a pivotal role in modulating immune responses, effectively impairing the recruitment and activation of cytotoxic immune cells in the vicinity of cancerous tissues.

Building on this insight, the research team engineered a novel therapeutic agent named SapC-DOPG. This drug leverages the unique biochemical signature of PDAC cells, selectively targeting phosphatidylserine—a phospholipid abnormally exposed on the surface of tumor cells. SapC-DOPG’s design borrows from a predecessor compound, SapC-DOPS, developed by Dr. Xiaoyang Qi, which is advancing through clinical trials for lung cancer treatment. However, SapC-DOPG distinguishes itself by its specificity to Hsp70 within pancreatic cancer cells, offering a targeted mechanism to disrupt tumor survival pathways and potentially reverse immune suppression.

Animal model testing of SapC-DOPG yielded promising results, demonstrating not only a good safety profile but also significant reductions in tumor size and prolonged survival rates. These preclinical outcomes suggest that SapC-DOPG could overcome some of the intrinsic resistance mechanisms that have rendered PDAC so refractory to existing treatments. The drug’s ability to specifically engage and neutralize Hsp70 function within the tumor microenvironment represents a significant leap forward in PDAC therapeutic research.

The implications of this research extend beyond merely shrinking tumors; by alleviating immunosuppression, SapC-DOPG may restore the immune system’s capacity to recognize and eliminate cancer cells more effectively. This dual action of direct tumor targeting and immune modulation represents a paradigm shift in treating notoriously resistant cancers such as PDAC. It raises the possibility of combining SapC-DOPG with other immunotherapeutic strategies, potentially transforming the clinical management of pancreatic cancer.

Dr. Ahmet Kaynak, a postdoctoral fellow and trainee associate member of the Cancer Center, spearheaded this groundbreaking project. He stresses the importance of comprehending the tumor microenvironment’s complexity to identify novel targets that conventional therapies have overlooked. “Understanding how Hsp70 fosters an immunosuppressive niche highlights a new vulnerability in pancreatic tumors,” Kaynak explained. Such insight is crucial in driving the development of therapies capable of dismantling the tumor’s defenses.

The research journey also illustrates the vital role of mentorship and institutional support, with Dr. Kaynak acknowledging the guidance of his mentor, Dr. Xiaoyang Qi. Their collaborative synergy has propelled the conceptual framework and translational progress from the lab bench toward clinical applicability. Moreover, the findings have garnered recognition within the scientific community, with one of the team’s manuscripts receiving accolades as the Trainee Associate Membership Paper of the Year within the Cancer Center.

Looking forward, the team aims to translate their preclinical successes into clinical trials, assessing SapC-DOPG’s safety and efficacy in pancreatic cancer patients. The existing clinical data on SapC-DOPS provides a reassuring safety precedent, bolstering hopes that this novel analog will similarly exhibit a favorable therapeutic index. If successful, SapC-DOPG could become an invaluable addition to the limited arsenal against PDAC, offering improved responses and potentially extending patient survival.

The profound challenges imposed by PDAC’s unique microenvironment demand innovative approaches grounded in molecular precision. This research embodies such innovation, combining deep mechanistic understanding with pharmaceutical ingenuity. Funded by the Pancreatic Cancer Action Network, and supported by travel grants facilitating dissemination at key academic forums, this project epitomizes the dynamic and collaborative nature of modern cancer research.

As presentations at prestigious venues such as the American Association for Cancer Research’s Special Conference in Pancreatic Cancer and the Frontiers in Cancer Immunotherapy Conference attest, these findings are reshaping conversations within the oncology community. They not only deepen scientific knowledge but also herald a new era of targeted therapies designed to outmaneuver the sophisticated defense mechanisms wielded by PDAC.

In conclusion, the discovery of Hsp70’s role in promoting immunosuppression and the development of SapC-DOPG mark a watershed moment in pancreatic cancer research. This work not only elucidates a previously underrecognized biological mechanism but also translates this knowledge into a tangible therapeutic advance with clear clinical promise. As the fight against pancreatic cancer continues, innovations like these pave the way toward more effective, durable treatments that can ultimately improve patient outcomes.

Subject of Research: Pancreatic ductal adenocarcinoma tumor microenvironment and therapeutic resistance mechanisms.

Article Title: Not specified in the source content.

News Publication Date: Not explicitly stated; research publications planned for January and April 2025; conference presentation scheduled for September 2025.

Web References:

• https://pubmed.ncbi.nlm.nih.gov/39941817/
• https://www.mdpi.com/2072-6694/17/7/1224
• https://www.uc.edu/news/articles/legacy/healthnews/2015/02/lung-cancer-may-be-treatable-with-use-of-sapc-dops-technology.html

References: Available in the linked journal articles.

Image Credits: None provided.

Keywords: Pancreatic cancer, PDAC, tumor microenvironment, Hsp70, immunosuppression, SapC-DOPG, molecular chaperones, cancer immunotherapy, chemotherapy resistance, targeted therapy, novel drug development, preclinical cancer research.

One of the forefront studies focuses on the unique population of adolescent and young adult (AYA) cancer survivors, individuals diagnosed between the ages of 18 and 39. This group has experienced rising cancer incidence rates over the past decade, yet their long-term health trajectories remain poorly understood. Led by oncologist and research scientist Alique Topalian, PhD, the investigation analyzes the baseline characteristics of AYA survivors receiving care in one of the nation’s few oncology primary care clinics specifically designed for cancer survivors. Utilizing a prospective clinical registry aimed at capturing longitudinal health outcomes, the team discovered that roughly 10% of the clinic’s patients were diagnosed during the AYA window.

Strikingly, 14% of these YAs had developed a second primary malignancy, underscoring an alarming predisposition for subsequent cancers in this demographic. Furthermore, cardiovascular diseases, particularly hypertension, affected about 60% of these patients, accompanied by frequent neurological, endocrine, and psychological comorbidities. Compounding these risks, lifestyle factors such as overweight and obesity prevailed in over half of the patients, with smoking histories—both former and current—adding to their vulnerability. Screening adherence varied, with breast cancer screening rates at 82%, colon cancer at 60%, and cervical cancer trailing at 40%. Topalian emphasizes the critical role oncology primary care providers must play in delivering comprehensive, lifelong monitoring and tailored preventative care to address the complex interplay of late effects and chronic conditions in this high-risk population.

Moving to hematologic malignancies, a separate investigation led by Eric Vick, MD, PhD, aims to quantify and characterize the overexpression of a protein isoform known as IRAK4L in acute myeloid leukemia (AML). Prior studies had recognized IRAK4L as hyperactive in AML cells, but precise expression levels and implications for chemotherapeutic resistance had remained elusive. By assessing animal models and patient-derived AML cell lines, Vick’s group demonstrated that most AML cancer cells express predominantly the IRAK4L isoform. When treated with azacitidine, a hypomethylating agent, and venetoclax, a targeted BCL-2 inhibitor, transient suppression of IRAK4L expression was observed. However, post-treatment recovery led to restoration of baseline protein levels, indicating that existing therapies only temporarily modulate this pro-tumorigenic pathway.

The implications of these findings extend to the development of next-generation pharmacologic inhibitors targeting IRAK4 as part of multifaceted therapeutic regimens. Vick anticipates that novel IRAK4 inhibitors may enter clinical trials imminently, presenting opportunities to overcome AML’s notorious ability to evade current treatment modalities. This research exemplifies the strategic shift toward precision medicine guided by molecular vulnerabilities inherent to specific leukemic subtypes.

Immunotherapy remains a dynamic frontier in oncology, highlighted by investigation into oncolytic viral therapies. The Phase 2 IGNYTE trial explores RP1, a genetically modified herpes simplex virus type 1 engineered to selectively infect and lyse tumor cells while stimulating systemic antitumor immunity. Under the guidance of Trisha Wise-Draper, MD, PhD, biosafety analyses of RP1’s behavior in patients with skin cancers revealed minimal viral dissemination beyond tumor sites. Detection of viral particles in blood, urine, and patient surfaces was negligible, with no secondary infections reported among close contacts or family members.

These safety data affirm that RP1’s replication remains tumor-restricted, a critical property to mitigate risks of contagion and systemic viral illness. Wise-Draper highlights that such reassuring biosafety profiles are essential for the continued evaluation of oncolytic viruses as viable immunotherapeutic agents. The ongoing trial aims to balance potent oncolytic activity with rigorous safety standards, setting the stage for broader incorporation of engineered viral platforms in oncology.

Another compelling study addresses the therapeutic void in adenoid cystic carcinoma (ACC), a rare, indolent yet treatment-resistant head and neck malignancy. Researchers under the mentorship of Wise-Draper initiated a Phase 2 clinical trial assessing amivantamab, a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and MET pathways. Previously approved for lung cancer-resistant variants, amivantamab was evaluated for its potential to surmount ACC’s notorious drug resistance. Among the 21 enrolled patients, partial tumor responses were noted, with one case achieving a 30% reduction in lesion size. Additionally, 10 patients demonstrated stable disease, culminating in a clinical benefit rate of 61%.

Importantly, the therapeutic regimen was well tolerated, with side effects confined primarily to manageable infusion reactions and skin rashes. Patient-reported quality of life remained stable throughout treatment. Researchers plan to conduct extensive molecular profiling of tumor specimens to identify predictive biomarkers that may refine patient selection and optimize therapeutic efficacy. This work lays the foundation for future amivantamab combination trials or expanded enrollment to validate its role in ACC management.

In a groundbreaking advancement for rare pediatric and young adult kidney cancers, James I. Geller, MD, reports findings from the national Phase 2 AREN1721 trial targeting translocation renal cell carcinoma (tRCC). This aggressive neoplasm is driven by chromosomal rearrangements involving TFE3 or TFEB transcription factors, resulting in aberrant gene expression and unchecked tumor growth. The trial evaluated a novel combination therapy pairing nivolumab, an immune checkpoint inhibitor that invigorates antitumor T-cell responses, with axitinib, a tyrosine kinase inhibitor that disrupts tumor angiogenesis.

Though the study enrolled just 13 patients aged 7 to 42, outcomes were promising. The dual therapy extended median progression-free survival to 10.5 months, markedly outperforming nivolumab monotherapy, which yielded a median progression of 1.8 months. Approximately one-third of combination recipients experienced partial tumor regression, a feat not observed with single-agent immunotherapy. Adverse event profiles were consistent with known drug toxicities and presented no unexpected safety concerns. Geller underscores the significance of these results, signaling a pivotal step toward improved treatment paradigms for tRCC, although he stresses the necessity for continued clinical innovation.

Collectively, these diverse research initiatives highlight the University of Cincinnati Cancer Center’s commitment to advancing oncologic knowledge across age groups, cancer types, and therapeutic modalities. From elucidating the complex long-term health needs of AYA cancer survivors to pioneering molecularly guided treatments in intractable malignancies, the findings presented at ASCO 2025 portend a future in which personalized cancer care is not an aspiration but a standard. As cancer patients live longer and treatments evolve, multidisciplinary endeavors such as these ensure that survivorship and quality of life receive as much attention as disease eradication.

Emerging themes across these studies include the urgent necessity for longitudinal monitoring of high-risk populations, interdisciplinary collaboration bridging basic science and clinical practice, and regulatory frameworks that support innovative trial designs. Moreover, advances in molecular profiling and immune oncology herald an era where therapeutic resistance can be anticipated and circumvented rather than merely managed. These strides bring hope that tomorrow’s cancer treatments will be smarter, more effective, and tailored uniquely to each patient’s biology and experience.

The spotlight on adolescent and young adult oncology exemplifies a critical recalibration in the oncology community’s approach to survivorship. Tailored prevention, comprehensive primary care, and enhanced provider-patient education form the cornerstones of this evolving paradigm. Likewise, efforts to refine immunotherapies and targeted agents shown in trials of IRAK4 inhibitors, oncolytic viruses, and antibody-drug conjugates underscore a nuanced understanding of cancer’s molecular underpinnings and immune evasion tactics.

As the ASCO Annual Meeting convenes, the collective momentum fosters optimism and underscores the vibrancy of cancer research. The University of Cincinnati Cancer Center’s multifaceted contributions, spanning from bench to bedside, reflect the broader shift in oncology toward integration, precision, and compassionate care for all patients, regardless of age, cancer type, or stage.

—

Subject of Research: Oncology research encompassing adolescent and young adult cancer survivorship, acute myeloid leukemia molecular targets, oncolytic virus safety, rare head and neck cancer therapies, and novel treatments for rare kidney cancers.

Article Title: University of Cincinnati Cancer Center Unveils Pioneering Research at ASCO 2025: Advances in AYA Survivorship, AML Molecular Targets, and Novel Cancer Therapies

News Publication Date: May 2025

Web References:
– IGNYTE trial (NCT03767348) – https://clinicaltrials.gov/study/NCT03767348

Keywords: Oncology, Adolescent and Young Adult (AYA) Survivorship, Acute Myeloid Leukemia (AML), IRAK4L Protein, Oncolytic Virus, RP1, Amivantamab, Adenoid Cystic Carcinoma (ACC), Translocation Renal Cell Carcinoma (tRCC), Immunotherapy, Targeted Therapy, Nivolumab, Axitinib

A particularly compelling study delves into the multifaceted role of interleukin-9 (IL-9), a small protein previously known to both exacerbate and inhibit tumor growth, contingent on cancer type. Until now, IL-9’s influence on HNC remained an enigma. The research, led by Sam Nusbaum, reveals that IL-9 expression is notably elevated in tumor tissues from patients with head and neck squamous cell carcinoma (HNSCC) compared to healthy individuals. Intriguingly, higher IL-9 mRNA levels correlated with poor patient survival, underscoring its potential as a prognostic biomarker. At the cellular level, IL-9 appears to induce the secretion of IL-6, a cytokine notorious for impairing the cytolytic function of immune cells tasked with eliminating cancer.

However, the story of IL-9 is far from linear. Experimental animal models demonstrated that increased IL-9 is paradoxically associated with reduced tumor size and weight, hinting at counterbalancing immune responses. This dichotomy suggests that IL-9’s role in tumorigenesis may be context-dependent, influenced by intricate molecular signaling and immune microenvironment dynamics. Nusbaum’s future investigations aim to dissect these pathways in precise molecular detail, shedding light on the dualistic nature of IL-9 in cancer progression and immune regulation.

Complementing this exploration, Lindsey Bachmann investigates signaling pathways integral to the function of natural killer (NK) cells—immune effectors pivotal in identifying and destroying cancer cells. Their research illuminates how blocking the CXCR2 receptor pathway impairs tumor growth in murine models, but only in the presence of NK cells and CD8+ T lymphocytes. CXCR2, a chemokine receptor, is crucial in directing immune cell trafficking and activation within tumors. This finding underscores the therapeutic potential of targeting immune cell receptor signaling to amplify anti-tumor immunity. Ongoing work will elucidate the mechanistic interplay between CXCR2 inhibition and immune effector cell behavior, potentially opening avenues to novel immunotherapies for HNC.

Amid these molecular insights, researchers led by Katelyn Jansen are pioneering efforts to improve noninvasive cancer diagnostics. Traditional tumor biopsies, while the gold standard for evaluating treatment response and disease progression, are often limited by accessibility and patient discomfort. Jansen’s team has standardized protocols for isolating peripheral blood mononuclear cells (PBMCs) from patient blood samples, demonstrating that delayed processing up to 24 hours does not compromise cell viability. This methodological advancement could revolutionize how clinicians monitor immunotherapy responses, allowing for safer, more frequent, and widely accessible assessments. The team plans to validate their findings across multiple institutions and compare PBMC-based analyses with conventional biopsy data to confirm efficacy.

Beyond diagnostics, Jansen also probed the synergistic potential of combining immunotherapy with radiation modalities in recurrent HNC. Specifically, she investigated the effects of proton therapy (PT) versus conventional X-ray radiation therapy (XRT) when paired with immune checkpoint inhibitors like anti-PD1 antibodies. Both PT and XRT effectively stymied tumor growth in vivo and increased immune cell infiltration, yet the addition of immunotherapy conferred only modest additional benefits. These preliminary data suggest that while radiation primes the tumor microenvironment for immune infiltration, the anticipated synergism with immunotherapy remains elusive in animal models. Future experimental designs will aim to optimize these combinatorial strategies, potentially by refining dosing schedules or leveraging novel immune modulators.

Turning to breast cancer, the University of Cincinnati team explored the impact of nonmuscle myosin IIA (NMIIA) within HER2-positive tumors—aggressive breast cancers marked by elevated HER2 protein levels driving rapid proliferation and metastasis. Through molecular interrogation, the team identified NMIIA’s interaction with HER3, a related receptor, modulating intracellular signaling pathways that contribute to drug resistance and metastatic behavior. Clinical correlations revealed that elevated NMIIA expression, particularly in lymphovascular invasion (LVI)-positive tumors, portends worse patient survival. This discovery positions NMIIA as a potential therapeutic target, and the lab is actively developing a novel NMIIA inhibitor. If successful, this approach could augment current HER2-targeted therapies, combating resistance and metastatic spread.

In an altogether different pathological context, lymphangioleiomyomatosis (LAM)—a rare lung disease characterized by cystic lung remodeling due to aberrant smooth muscle-like cell proliferation—has been the focus of cutting-edge metabolic research. First author Evans Abor examined the enzyme PHGDH and its regulatory nexus with mTORC1, a signaling hub known to drive LAM progression. Remarkably, PHGDH expression was markedly increased in diseased tissues. Pharmacological inhibition of PHGDH not only induced apoptosis in LAM cells but also impaired key metabolic processes such as mitochondrial function and macromolecular biosynthesis, which are essential for tumor cell viability. Notably, combinatorial treatment with rapamycin, an established mTORC1 inhibitor, potentiated autophagy—a cellular clearance mechanism—highlighting a promising therapeutic synergy. This metabolic angle opens vast potential for overcoming therapeutic resistance and curbing disease progression.

The Cancer Center’s portfolio of research presented at AACR 2025 also includes advanced studies in colorectal cancer, where co-targeting HER family receptors and mutant KRAS mutations has shown efficacy, and investigations into the role of Stat1 in tumor immunity within tuberin-deficient cells, a finding with implications for LAM pathology. These multifaceted efforts underscore the Center’s broad commitment to deciphering the complex molecular and immunological landscapes that define cancers and rare diseases.

Collectively, these studies highlight the burgeoning era of precision oncology, wherein deep molecular insights are translated into targeted, patient-centric interventions. The convergence of immunology, molecular biology, and translational medicine embodied in this research holds transformative promise: personalized treatments informed by tumor and immune profiling, minimally invasive diagnostics, and combination therapies that outmaneuver tumor resistance mechanisms.

As the AACR Annual Meeting approaches, the University of Cincinnati Cancer Center’s contributions stand poised to ignite new conversations and collaborations, catalyzing advancements that may soon reshape clinical cancer care. The synthesis of fundamental discovery and applied research presented by these emerging scientists and established investigators exemplifies the dynamic pursuit of innovative solutions to some of oncology’s most pressing challenges.

Subject of Research: Head and neck cancer, breast cancer, lymphangioleiomyomatosis, cancer immunotherapy, metabolic vulnerabilities in rare diseases.

Article Title: University of Cincinnati Cancer Center Unveils Novel Insights at AACR 2025: IL-9’s Paradoxical Role, Immune Signaling Pathways, and Emerging Therapeutic Targets

News Publication Date: Information not provided.

Web References: Information not provided.

References: Information not provided.

Image Credits: Information not provided.

Keywords: Head and neck cancer, breast cancer, tumor growth, cancer immunotherapy, inhibitory effects, animal models, peripheral blood mononuclear cells, radiation therapy, NK cell receptor signaling, cell responses, cancer research.